1 May 2013 07:00
BEXIMCO PHARMACEUTICALS LTD.
1th May, 2013
Notification of Preliminary Results and Annual General Meeting
Beximco Pharmaceuticals Ltd. ("BPL" or "Company": AIM Symbol: BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 30th April, 2013 has decided the following:
1. | To recommend the approval of the Financial Statements for the year ended 31 December 2012 | : | The Audited Financial Statements for the year ended 31 December 2012 has been approved. The full accounts are expected to be announced by 15th May 2013 |
2. | Date & Time of 37th AGM of the Company for the year 2012 | : | 29 June, 2013 at 10.00 am |
3. | Venue of AGM | : | Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh |
4. | Proposed Dividend for the year ended 31 December 2012 | : | 15% Stock Dividend (i.e. 15 shares for every 100 shares held) |
5. | Record date | : | 20 May, 2013 |
6. | Net Asset Value as at 31 December 2012 | : | Taka 18,408,161,859 |
7. | Net Asset Value per Share as at 31 December 2012 | : | Taka 60.43 |
8. | Earnings per share (EPS) for the year ended 31 December 2012 | : | Taka 4.33 |
9. | Net Operating Cash Flow per share for the year ended 31 December 2012 | : | Taka 6.10 |
For further information please visit www.beximco-pharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing DirectorTel: +880 2 861 9151, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 8618220-1, Ext 10140
Libertas Capital Corporate Finance (Nomad)
Thilo Hoffmann
Tel: +44 (0)20 7569 9650
Daniel Stewart & Company (Broker)
Paul Shackleton
James Thomas
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Susan Stuart / Victoria Foster-MitchellTel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.
Beximco Pharma (BXP)